These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 22429766)

  • 41. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
    Zhao S; Tang J; Shao S; Yan Y
    Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?
    van Renterghem K; Van Koeveringe G; Van Kerrebroeck P
    Int Urol Nephrol; 2007; 39(4):1107-13. PubMed ID: 17602307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Murad AS; Down L; Davey Smith G; Donovan JL; Athene Lane J; Hamdy FC; Neal DE; Martin RM
    Int J Cancer; 2011 Mar; 128(6):1442-8. PubMed ID: 20506261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study.
    Shebl FM; Sakoda LC; Black A; Koshiol J; Andriole GL; Grubb R; Church TR; Chia D; Zhou C; Chu LW; Huang WY; Peters U; Kirsh VA; Chatterjee N; Leitzmann MF; Hayes RB; Hsing AW
    Br J Cancer; 2012 Jun; 107(1):207-14. PubMed ID: 22722313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
    J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
    Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH; Kim Y; Park YW; Lee DG
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [FEATURES OF CLINICAL COURSE AND MORPHOMETRIC PARAMETERS OF BENIGN PROSTATIC HYPERPLASIA IN MEN WITH METABOLIC SYNDROME AND ANDROGEN DEFICIENCY].
    Tyuzikov IA; Grekov EA; Kalinchenko SY
    Urologiia; 2015; (5):66-9. PubMed ID: 26859941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
    Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
    Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A cohort study of Chinese elderly males.
    Chen W; Man S; Wang B; Kadeerhan G; Huang X
    Low Urin Tract Symptoms; 2022 May; 14(3):170-177. PubMed ID: 34882977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry.
    Malde S; Patel A; Martínez-Piñeiro L; de la Taille A; Bjartell A; Tubaro A; Witjes W; Caris C
    Eur Urol Focus; 2021 Jan; 7(1):178-185. PubMed ID: 31345783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
    Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
    BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Ultrasound indicators of the prostate, urinary bladder and uroflowmetry parameters in the diagnosis of infravesical obstruction in men with benign prostatic hyperplasia].
    Krivoborodov GG; Efremov NS; Bolotov AD
    Urologiia; 2017 Oct; (5):9-14. PubMed ID: 29135135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
    Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
    Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
    Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
    BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.